Saturday, November 2, 2024

CATEGORY

Eli Lilly

Tech Giants Race to Develop Quantum Computing Capabilities

Key TakeawaysCompanies must prioritize ethical guidelines to prevent misuse of quantum technology. Robust security measures are essential to protect sensitive information from quantum...

Lilly’s Mirikizumab Surpasses Ustekinumab in Reducing Crohn’s Disease Inflammation: 52-Week Study

Key TakeawaysMirikizumab outperformed ustekinumab in achieving histologic response at Week 52 in patients with Crohn’s disease, regardless of prior biologic treatments. This marks...

Groundbreaking Data: Lilly’s EBGLYSSâ„¢ Provides Long-Term Disease Control for Atopic Dermatitis Patients

Key TakeawaysLilly's EBGLYSSâ„¢ (lebrikizumab-lbkz) demonstrated sustained skin clearance for up to three years in over 80% of patients with moderate-to-severe atopic dermatitis. Nearly...

Lilly Unveils $4.5 Billion Investment in Revolutionary “Medicine Foundry” to Transform Drug Manufacturing and Global Clinical Supply

Key TakeawaysEli Lilly announced the creation of a groundbreaking $4.5 billion "Lilly Medicine Foundry" in Indiana, aiming to revolutionize drug production and accelerate...

Diabetes and Weight-Loss Drugs Mounjaro and Zepbound No Longer in Shortage, FDA Reinforces Compounding Restrictions

Key TakeawaysThe FDA has officially declared the end of the shortage for Eli Lilly’s Mounjaro and Zepbound, signaling improved availability of these popular...

ALZHEIMER’S Treatment Receives Approval in Japan for Early Symptomatic Stages

Key TakeawaysKisunlaâ„¢ (donanemab-azbt) has been approved for treating adults in the early symptomatic stages of Alzheimer's, including mild cognitive impairment (MCI) and mild...

Dermatitis: FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis

Key TakeawaysEbglyss (lebrikizumab-lbkz) is approved for treating moderate-to-severe atopic dermatitis in patients 12 years and older. Ebglyss targets the IL-13 pathway, addressing systemic...

Medicare Spending on Wegovy Could Surge by $145 Billion

Key TakeawaysCovering Wegovy® (semaglutide) for heart disease risk could increase Medicare Part D spending by $34 billion to $145 billion annually. Medicare currently...

Obesity and Related Metabolic Conditions Lead HAYA Therapeutics and Eli Lilly to Collaborate on Novel RNA-Based Targets

Key TakeawaysThe collaboration between HAYA Therapeutics and Eli Lilly aims to leverage RNA-based therapies to target the regulatory genome, focusing on treating obesity...

Obesity Treatment Advances: Lilly Expands Access with Single-Dose Vials of Zepbound

Key Takeaways:Eli Lilly has introduced single-dose vials of Zepbound (tirzepatide) in 2.5 mg and 5 mg doses, expanding treatment options for adults with...

Tirzepatide Reduces Type 2 Diabetes Risk by 94% in Pre-Diabetic Adults

Tirzepatide has emerged as a groundbreaking treatment with the potential to dramatically alter the trajectory of type 2 diabetes prevention in individuals with pre-diabetes...

Gene Therapy Shows Promise in Restoring Hearing for Children

Gene therapy is delivering promising results in restoring hearing for children with profound genetic deafness. Early this year, Regeneron revealed that its DB-OTOF gene...

FDA Releases KISUNLA Snapshot: A New Alzheimer’s Treatment

The FDA has published a comprehensive Drug Trials Snapshot for KISUNLA, an amyloid beta-directed antibody developed by Eli Lilly and Company. Approved on July...

Eli Lilly Raises Sales Forecast by $3B as Diabetes and Weight Loss Drugs Soar

Eli Lilly has significantly raised its revenue guidance for 2024, fueled by the robust performance of its diabetes and weight loss drugs, particularly Zepbound...

Obesity Treatment Back on Track as Eli Lilly’s Zepbound Returns to Market After Extended Shortage

After months of supply challenges, the U.S. Food and Drug Administration (FDA) has announced that Eli Lilly's popular diabetes medication Mounjaro, and its obesity...

Latest news